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Background and Aims. 5-year survival in patients with pancreatic cancer is poor. Surgical resection is the only potentially curative
resection. The results of adjuvant treatment either with chemotherapy or with radiotherapy have been contradictory and the
incidence of local-regional recurrence remains high. If local-regional recurrence is controlled survival may be expected to increase.
Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) may be used in order to control local-regional recurrences.
The purpose of the study is to identify the eﬀect of HIPEC in patients with pancreatic cancer undergoing potentially resection.
Patients and Methods. From 2007–2011, 21 patients, mean age 69.4 ± 9.5 (50–86) years, underwent tumor resection, and HIPEC
with gemcitabine. The hospital mortality and morbidity rate was 9.5% and 33.3%, respectively. 5-year and median survival was
23% and 11 months, respectively. The recurrence rate was 50% but no patient developed local-regional recurrence. No patient was
recorded with gemcitabine-induced toxicity. Conclusions. This clinical study of 21 patients is the ﬁrst to combine an R0 pancreas
cancer resection with HIPEC. Increased morbidity and mortality from intraoperative gemcitabine was not apparent. Patients with
pancreatic cancer undergoing potentially curative resection in combination with HIPEC may be oﬀered a survival beneﬁt. Data
suggested that local-regional recurrences may be greatly reduced. Further studies with greater number of patients are required to
conﬁrm these ﬁndings.
1.Introduction
Pancreatic cancer is one of the most frequent causes of
cancer-related deaths in the western world. The overall 5-
year survival rate after potentially curative resection does
not exceed 15% in most series [1–3], although in high
volume centers it may be as high as 20–25% [4, 5]. Surgical
resection remains the single potentially curative option
but only 10–15% of the diagnosed tumors are eligible for
resection [6–9]. Increase of long-term survival may result
either if the proportion of patients with locally unresectable
tumors decreases or if treatments that may control disease
recurrence, and particularly the local-regional ones, are
developed.
In 1985 the Gastrointestinal Study Group showed that
adjuvant chemoradiation oﬀers signiﬁcant survival beneﬁt
after surgical resection in patients with pancreatic cancer
[10] but a decade later this was disputed by the study
conducted by EORTC [11]. The ESPAC study showed that
chemotherapy only oﬀers a survival beneﬁt [12]. Recent
studies have shown that chemoradiation may be a favorable
option for patients with resectable tumors [13]. A review2 Gastroenterology Research and Practice
of these manuscripts document that the data concerning
adjuvant treatment for resectable pancreatic cancer are
contradictory.
The sites of recurrence after curative resection are the
liver in 50–60%, the peritoneal surfaces in 40–50%, and the
pancreaticbedin50%ofthecases[14].Thepathophysiology
of local-regional recurrence after R0 resection remains an
enigma. It may be the result of metastases undetected
on imaging or laparotomy. Or tumor dissemination and
implantation of cancer emboli at the resection sites may
occurwithpancreatectomy[15].Ifthisistruethenintraperi-
toneal chemotherapy may be the treatment that has a
beneﬁcial impact on overall survival by reducing the number
of local-regional recurrences. Intraperitoneal chemotherapy
has the capability to eradicate the microscopic cancer emboli
and reduce the incidence of local-regional recurrences. It is
obvious that there is an absolute need for adjuvant treatment
in addition to surgical resection.
The purpose of the study is to identify the poten-
tial beneﬁts of hyperthermic intraperitoneal intraoperative
chemotherapy (HIPEC) with gemcitabine in patients that
undergo R0 resection for pancreatic cancer.
2. Patients-Methods
From April 2007 until August 2011, 21 patients with
resectable pancreatic cancer, without distant metastatic
lesions as assessed by routine preoperative staging (physical
examination, CT-scan, MRI, and bone scanning) were
enrolled in the study. The study was approved by the Ethical
Committee of the hospital and patients signed an informed
consent prior to accepting this therapeutic approach.
The diagnosis was possible by physical examination,
hematological-biochemical examination, tumor markers
(CEA, CA 19-9, CA-125), CT abdominal and thoracic scan
or MRI, and bone scanning. No preoperative histological
examination was performed.
Patientsbetween16–90yearsofage,withsatisfactorycar-
diopulmonary function, satisfactory renal function (blood
urea level <50mg/dL and creatinine level <1.5mg/dL),
satisfactory liver function (other than hepatobiliary obstruc-
tion), with white blood cell count >4000/mL, platelet
count >150.000/mL, and acceptable performance status
(Karnofsky performance status >50%) were included in the
study.
Patients with evidence of distant metastatic disease
(liver, osseous, brain and pulmonary), with prior antitumor
therapy, with prior malignancy at risk for recurrence (except
for basal cell carcinoma or in situ carcinoma of the cervix
adequately treated), with poor performance status (Karnof-
sky performance status <50%), with psychiatric diseases or
addictive disorders, and pregnant women were not included
in the study.
Patients with periampullary tumors were not included
in the study. Patients with resectable pancreatic cancer and
limited peritoneal metastases for whom CC-0 or CC-1
cytoreduction could be possible, were included in the study.
2.1. Treatments. Patients with cancer of the head of the pan-
creas underwent subtotal pancreatoduodenectomy (Kausch-
Whipple procedure). Distal pancreatectomy was used for
cancer of the body or the tail of the pancreas. After tumor
resection and before the reconstruction of the alimentary
tract, HIPEC was performed for 60min at 42–43◦Cw i t h
gemcitabine at a dose of 1000mg/m2. HIPEC was admin-
istered using the open (Coliseum) technique. A heater
circulator with two roller pumps, one heat exchanger, one
reservoir, and an extracorporeal system of two inﬂow and
twooutﬂowtubes,and4thermalprobeswasusedforHIPEC
(Sun Chip, Gamida Tech, France). A prime solution of 2-3
liters of normal saline was instilled prior to administration
of the cytostatic drug and as soon as the mean abdominal
temperature reached 40◦C gemcitabine was instilled in the
abdomen.
During perfusion adequate ﬂuids were administered in
addition to dopamine at a diuretic dose of 3µg/K.b.w., in
order to maintain diuresis at 500mL/h. Dopamine was also
used after surgery for 24 hours to maintain diuresis at the
same levels.
The reconstruction of the alimentary tract was per-
formed after the completion of HIPEC. After subtotal pan-
creatoduodenectomy the reconstruction was always made
with an end-to-side pancreato-jejunal anastomosis, end-to-
side choledocho-jejunal anastomosis, followed by a Roux-
en-Y gastrointestinal anastomosis with a second jejunal loop.
Cytoreductive surgery with standard peritonectomy pro-
cedures was used for the treatment of peritoneal metastases
whenever they were found [16]. A CC-0 operation did
not leave behind macroscopically visible tumor. A CC-1
operation had residual tumor less than 2.5mm in its largest
diameter [17].
All resected specimens were sent for histopathological
examinationandcompletestaging.StageIIIpatientsreceived
additional systemic chemotherapy with gemcitabine and 5-
FU.
2.2. Followup. All patients were followed up at 3-month
intervals with physical examination, hematological, and
biochemical examinations, tumor markers (CEA, CA 19-9,
CA-125), and thoracic and abdominal CT. Recurrences and
the sites of recurrence were recorded.
2.3. Statistical Analysis. The proportion of patients with a
given characteristic was compared by chi-square analysis or
by Pearson’s test. Diﬀerences in the means of continuous
measurementweretestedbytheStudent’st-test.Thesurvival
curves were obtained with the Kaplan-Meier method. A two-
tailedP valueof<0.05wasconsideredstatisticallysigniﬁcant.
3. Results
The mean age of the patients was 69.4 ± 9.5 (50–86) years.
The characteristics of the patients are listed in Table 1.
Histopathology revealed that all patients had pancreatic
cancer. One patient with cancer of the pancreatic tail
and extensive peritoneal carcinomatosis underwent distalGastroenterology Research and Practice 3
Table 1: Patients’ general characteristics.
Male/Female No. of patients %
9/12 42.9/57.1
Tumor anatomic distribution
Head 17 81
Body 1 4.8
Tail 3 14.3
Performance status
90–100% 15 71.4
70–80% 5 23.8
50–60% 1 4.8
Tumor inﬁltration
T1 14 . 8
T2 3 14.3
T3 17 81
Nodal inﬁltration
N0 9 42.9
N1 12 57.1
TNM stage
I 3 14.3
II 6 28.6
III 12 57.1
Degree of diﬀerentiation
G1 41 9
G2 9 42.9
G3 8 38.1
Residual tumor
R0 20 95.3
R1 14 . 7
pancreatectomy and near complete cytoreduction (CC-1)
combined with HIPEC. This was deﬁned as R1 surgery
because of possible residual tumor <2.5mm left on the
peritoneal surfaces of the mesentery. All the other patients
had resectable tumors and underwent R0 resection of the
tumor combined with HIPEC. Seventeen patients with
tumor of the head of the pancreas underwent subtotal
pancreatoduodenectomy.Theotherfourpatients(threewith
cancerofthetailandonewithcancerofthebody)underwent
distal pancreatectomy.
The hospital morbidity rate was 33.3% (7 patients). The
recorded complications are listed in Table 2. One patient
was reoperated because of postoperative bleeding that was
successfully controlled. One further patient was reoperated
because the choledochojejunal anastomosis failed, but was
successfullycontrolledbyT-tubeinsertion.Theotherpatient
with anastomotic leak underwent conservative treatment.
The rate of reoperation was 9.5%. Only one patient was
recorded with grade II neutropenia that did not require
speciﬁc treatment. The hospital mortality rate was 9.5% (2
patients). One of them died because of ARDS and the other
one of sepsis with an unknown primary site. The mean
hospital length of stay was 18 days.
Table 2: Postoperative complications.
No. of patients %
Postoperative bleeding 1 4.8
Anastomotic leak 2 9.5
Acute respiratory distress syndrome 2 9.5
Sepsis 1 4.8
Grade II neutropenia 1 4.8
The5-yearsurvivalratewas23%andthemediansurvival
11 months (Figure 1). Eleven stage III patients received
systemic adjuvant chemotherapy with gemcitabine. One of
the patients with stage II disease died during the immediate
postoperative period. The median disease-free survival time
was 5 months. The median follow-up time was 7 months.
During followup 9 patients (50%) were recorded with
recurrence. Three of them were stage II and 6 were stage III.
All these patients had liver metastases and no locoregional
recurrence, was recorded.
Currently 8 patients (38.1%) are alive without evidence
of disease, 10 patients (47.6%) died because of recurrence,
and 3 patients (14.3%) died of other causes unrelated to
cancer.
4. Discussion
Although the pathophysiology of local-regional recurrence is
unclear it has been assumed that the resection of a tumor
located within narrow margins of resection may result in
tumor dissemination because of interstitial tissue trauma,
or severed lymphatics leaking cancer cells, or from venous
blood loss contaminated by cancer cells. The disseminated
cancer emboli are trapped in ﬁbrin, stimulated by growth
factors, and give rise to local-regional recurrent tumors
within months-years after initial surgical manipulations
[15]. The eradication of the entrapped microscopic cancer
emboli may be possible by using intraperitoneal chemother-
apy. Intraperitoneal chemotherapy has been shown to be
very eﬀective in carcinomatosis from colorectal cancer
either as HIPEC or as early postoperative intraperitoneal
chemotherapy (EPIC) under normothermia. The advantage
of intraperitoneal chemotherapy is the high drug level that
can be achieved by low systemic exposure [18].
Gemcitabine as systemic adjuvant treatment has been
proved to be very eﬀective in high risk patients undergo-
ing potentially curative resection [19]. However, systemic
chemotherapy has not been conﬁrmed to assist in control
of local disease. In contrast, it has been shown both from
laboratory and clinical studies that the intraperitoneal use of
gemcitabine may eﬀectively target local disease. Laboratory
studies have shown that the intraoperative use of gemc-
itabinemayeﬀectivelypreventthedevelopmentofperitoneal
metastases. In addition early postoperative intraperitoneal
chemotherapy may reduce the extent of peritoneal metas-
tases [20]. Our data shows that the intraperitoneal use of
gemcitabine in patients having pancreatectomy is well toler-
ated and does not produce severe toxicity. After all, only one4 Gastroenterology Research and Practice
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Figure 1: Overall survival of 21 patients with pancreatic cancer
treated with complete resection plus hyperthermic intraoperative
intraperitoneal chemotherapy.
patient developed grade II neutropenia that did not require
any speciﬁc treatment. Intraperitoneal gemcitabine may be
incriminated for the two anastomotic failures although it
has not been proved. The large concentration of gemcitabine
sustained in the peritoneal space and the low plasma
concentration are ﬁndings supporting its intraperitoneal use
[21].
The theoretical advantage of intraperitoneal gemcitabine
has been conﬁrmed by clinical and laboratory studies.
Pharmacokineticstudiesofintraperitonealadministrationin
a rat model have demonstrated that the area under the curve
ratio of intraperitoneal to systemic drug exposure is closely
relatedtotheintraperitonealdoseandtissuesamplesshowed
increased drug concentration when administered with heat
[22]. Preliminary pharmacokinetic data in patients with
resectable pancreatic cancer that underwent HIPEC with
gemcitabine at a dose of 1000mg/m2 s h o w e dm a r k e dl o c a l -
regional drug exposure [23]. In addition, the intraperitoneal
useofgemcitabineinclinicalpracticehasshownequalresults
to platinum-based regimens in women with ovarian cancer
[24]. These data taken together suggest that studies to test
gemcitabine in patients with resectable pancreatic cancer are
justiﬁed. It appears that intraperitoneal chemotherapy may
have a favorable eﬀect in eradicating microscopic cancer
emboli not only locoregionally but also in the portal venous
circulation. It has been found that the measured portal
vein concentrations exceeded the measured concentration in
other vessels when 5-FU was administered intraperitoneally
[25]. Although the number of the included patients is very
smallandthemedian follow-uptime short,no patientdevel-
oped local-regional recurrence. This implies that HIPEC
is likely to be eﬀective in eradicating residual microscopic
cancer emboli at the peritoneal surfaces.
5. Conclusions
Our preliminary results in the resection of pancreatic cancer
with HIPEC using gemcitabine have shown that there
may be a survival advantage even in patients with nodal
involvement.
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